Quick Answer
Glucomannan Dietary Fiber Meta-Analysis has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: Obesity is a globally prevalent metabolic disorder closely associated with gut microbiota dysbiosis.
Key Takeaways
- 01Obesity is a globally prevalent metabolic disorder closely associated with gut microbiota dysbiosis. [Hu B (2026)]
- 02faecium or exogenous LEA supplementation improved obesity-associated metabolic phenotypes. [Hu B (2026)]
- 03Furthermore, using a high-content screening system and an in vitro fermentation model, we found that the dietary fiber glucomannan exerted anti-obesity effects by promoting the growth of E. [Hu B (2026)]
- 04However, the precise roles of gut microbiota and microbial metabolism in this disease remain unclear. [Hu B (2026)]
The current Migaku evidence database contains 2 reusable source documents for Glucomannan Dietary Fiber Meta-Analysis. This answer focuses on strength of evidence and what the studies can or cannot prove.
- Obesity is a globally prevalent metabolic disorder closely associated with gut microbiota dysbiosis. [Hu B (2026); evidence level 4]
- faecium or exogenous LEA supplementation improved obesity-associated metabolic phenotypes. [Hu B (2026); evidence level 4]
- Furthermore, using a high-content screening system and an in vitro fermentation model, we found that the dietary fiber glucomannan exerted anti-obesity effects by promoting the growth of E. [Hu B (2026); evidence level 4]
- However, the precise roles of gut microbiota and microbial metabolism in this disease remain unclear. [Hu B (2026); evidence level 4]
- Effects of OKGM on metabolic health was evaluated by a 13-week oral toxicity study in ICR mice, in compliance with OECD Guideline 408 (OECD, 1998). [Li Yao (2024); evidence level 4]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources